Core Insights - Atea Pharmaceuticals is advancing its Phase 3 clinical trials for the combination regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV), with ongoing patient enrollment in the C-BEYOND trial in the US and Canada, and plans to initiate the C-FORWARD trial globally [4][11][12] - The company reported promising Phase 2 results, indicating a high sustained virologic response (SVR12) rate of 98% among treatment-adherent patients and 95% overall, showcasing the regimen's potential as a best-in-class treatment for HCV [7][11] - Atea's financial results for Q1 2025 show a decrease in research and development expenses to $29.6 million, down from $57.6 million in Q1 2024, attributed to the completion of a previous COVID-19 trial and a focus on HCV development [16][20] Company Updates - Atea is hosting a virtual key opinion leader (KOL) investor event on May 14, 2025, to discuss HCV treatment challenges and the potential of its drug regimen, replacing the traditional earnings call for Q1 2025 [5][6] - The company has engaged Evercore to explore strategic alternatives to enhance shareholder value, including potential partnerships or acquisitions, while also reducing its workforce by approximately 25% to save around $15 million through 2027 [14][15] Financial Performance - As of March 31, 2025, Atea reported cash, cash equivalents, and marketable securities totaling $425.4 million, a decrease from $454.7 million at the end of 2024 [15][22] - The net loss for Q1 2025 was $34.3 million, compared to a net loss of $63.2 million in Q1 2024, reflecting improved operational efficiency [20][22] Clinical Development - The Phase 3 program includes two trials, C-BEYOND and C-FORWARD, each aiming to enroll approximately 880 treatment-naïve patients, comparing the BEM/RZR regimen to the standard sofosbuvir and velpatasvir regimen [11][12] - The primary endpoint for both trials is achieving HCV RNA levels below the lower limit of quantitation at 24 weeks, ensuring consistent evaluation across patient groups [12][13]

Midland, Texas, May 12, 2025 (GLOBE NEWSWIRE) -- Natural Gas Services Group, Inc. (“NGS” or the “Company”) (NYSE:NGS), a leading provider of natural gas compression equipment, technology, and services to the energy industry, today announced financial results for the three months ended March 31, 2025. The Company also raised the high-end of its full-year 2025 Adjusted EBITDA guidance to $79 million, citing continued strength in its business and growing demand across its fleet. First Quarter 2025 Highlights R ...

Reports Net Loss of $17.6 Million or $0.40 per Diluted Share, and Adjusted EBITDA of ($16.1) MillionCLAYTON, Mo., May 12, 2025 (GLOBE NEWSWIRE) -- FutureFuel Corp. (NYSE: FF) (“FutureFuel”), a manufacturer of custom and performance chemicals and biofuels, today announced financial results for the first quarter ended March 31, 2025. First quarter 2025 Financial Highlights (all comparisons are with the first quarter of 2024) Revenues were $17.5 million, a decrease of 70% or $40.7 million compared to $58.3 mil ...

Q1 Revenue Growth of 0.8%, Currency Neutral Growth of 2.6%Q1 Annual Subscription Revenue Growth of 5.4%, Currency Neutral 7.2%Annual Subscription Revenue Rose to 57.2% of Total Revenue in Q1Updates 2025 Guidance to Reflect FX Impacts, while Reaffirming Currency Neutral Revenue Growth Outlook NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Getty Images Holdings, Inc. (“Getty Images” or the “Company”) (NYSE: GETY), a preeminent global visual content creator and marketplace, today reported financial results for the ...

SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2025, together with other business updates. Financial Highlights: Quarterly revenue of $46.9 million, Net loss of $(52.9) million (including a goodwill impairment of $12.4 million), and Adjusted EBITDA of $(10.5) million; andRevenue ...

First Quarter 2025 Revenue of $36.0 million; Highest Q1 in HistoryOMAHA, Neb., May 12, 2025 (GLOBE NEWSWIRE) -- Exodus Movement, Inc. (NYSE American: EXOD) ("Exodus"), a leading self-custodial cryptocurrency platform, today announced its unaudited results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights (Unaudited) In USD millions, except percentagesQ1 2025Q1 2024 % Change Revenue<td style="max-width:2%; width:2%; min-width:2%;;padding-right: ...

REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended March 31, 2025 and provided a corporate update. “During the first quarter of 2025 we made great progress ad ...

JACKSONVILLE, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- FRP Holdings, Inc. (NASDAQ-FRPH) – FRP Holdings is a real estate asset developer and manager across three differing asset classes including Multifamily, Industrial and Commercial, and Mining and Royalty Lands. Net Income Results - Net income for the first quarter of 2025 was $1,710,000 or $.09 per share versus $1,301,000 or $.07 per share in the same period last year. Executive Summary and Analysis – In the first quarter, the Company saw a 31% improvement ...

– Q1 Total Revenue up 6% YoY to $117.8 Million –– Q1 Net Income up Materially YoY to $10.0 Million or $0.23 Earnings per Share –– Q1 Operating Cash Flow up ~2x YoY to $38.4 Million –– Q1 Adjusted EBITDA up ~3x YoY to $19.3 Million – TERRE HAUTE, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- Hallador Energy Company (Nasdaq: HNRG) (“Hallador” or the “Company”) today reported its financial results for the first quarter ended March 31, 2025. “We are pleased with our first quarter performance as we returned to top line ...

– Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2 2025 – – Initiated Explore-OSA Phase 2 Trial in Q1 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing med ...